Skip to main content

Table 1 Association of high protease expression by stromal cells with other prognostic factors

From: The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis

Parameter

Cases

MMP-14

MMP-2

TIMP-2: stromal cells

TIMP-2: cancer cells

  

Number

Percentage Pos

p value

Number

Pecentage Pos

p value

Number

Percentage Pos

p value

Number

Percentage Pos

p value

Age years

             

   <50

160

59

36.9

0.034

85

53.1

0.19

58

36.3

0.79

59

36.9

0.14

   ≥50

379

105

27.7

 

178

47.0

 

142

37.5

 

166

43.8

 

Tumor size cm

             

   <3

297

93

31.3

0.98

146

49.2

0.65

118

39.7

0.14

122

41.1

0.83

   ≥3

207

65

31.4

 

106

51.2

 

69

33.3

 

87

42.0

 

Involved lymph nodes

             

   0

190

46

24.2

 

81

42.6

 

71

37.4

 

80

42.1

 

   1 to 3

166

61

36.7

0.036

93

56.0

0.041

69

41.6

0.29

75

45.2

0.52

   >3

174

54

31.0

 

84

48.3

 

58

33.3

 

68

39.1

 

Peritumoral lymphovascular invasion

             

   Yes

143

50

35.0

0.15

76

53.1

0.097

50

35.0

0.15

64

44.8

0.027

   No

75

19

25.3

 

31

41.3

 

19

25.3

 

22

29.3

 

Histological grade

             

   I

54

18

33.3

 

25

46.3

 

19

35.2

 

23

42.6

 

   II

277

81

29.2

0.69

133

48.0

0.83

109

39.4

0.59

119

42.9

0.82

   III

197

64

32.5

 

99

50.3

 

69

35.0

 

79

40.1

 

Nuclear grade

             

   I

94

20

21.3

 

40

42.6

 

39

41.5

 

42

44.7

 

   II

307

98

31.9

0.066

158

51.5

0.27

105

34.2

0.22

128

41.7

0.79

   III

127

45

35.4

 

59

46.5

 

53

41.7

 

51

40.2

 

Histological type

             

   Invasive ductal carcinoma

470

156

33.2

0.0006

238

50.6

0.021

164

34.9

0.003

28

43.1

0.83

   Others

65

8

12.3

 

23

35.4

 

35

53.8

 

196

41.7

 

DNA ploidy

             

   Diploid

143

37

25.9

0.09

64

44.8

0.18

58

40.6

0.59

60

42.0

0.99

   Non-diploid

332

112

33.7

 

171

51.5

 

126

38.0

 

139

41.9

 

Estrogen receptors

             

   Negative

143

53

37.1

0.055

76

53.1

0.22

59

41.3

0.25

61

42.7

0.89

   Positive

374

106

28.3

 

176

47.1

 

134

35.8

 

157

42.0

 

Progesterone receptors

             

   Negative

219

74

33.8

0.21

109

49.8

0.72

88

40.2

0.26

95

43.4

0.60

   Positive

297

85

28.6

 

143

48.1

 

105

35.4

 

122

41.1

 

HER-2/neu expression

             

   Negative

437

121

27.7

0.0042

204

46.7

0.042

158

36.2

0.34

179

41.0

0.45

   Positive

102

43

42.2

 

59

57.8

 

42

41.2

 

46

45.1

 

p53

             

   Negative

374

107

28.6

0.12

186

49.7

0.53

132

35.3

0.24

149

39.8

0.30

   Positive

152

54

35.5

 

71

46.7

 

62

40.8

 

68

44.7

 

HSP-27

             

   Negative

204

61

29.9

0.097

97

47.5

0.02

63

30.9

0.0024

70

34.3

0.0003

   Positive

157

60

38.2

 

94

59.9

 

73

46.5

 

84

53.5

 

Cathepsin D cancer cells

             

   Negative

324

94

29.0

0.29

151

46.6

0.21

111

34.3

0.071

127

39.2

0.102

   Positive

207

69

33.3

 

87

52.2

 

87

42.0

 

96

46.4

 

Cathepsin D stromal cells

             

   Negative

303

78

25.7

0.0035

130

42.9

0.0013

106

35.0

0.21

116

38.3

0.047

   Positive

226

85

37.6

 

129

57.1

 

91

40.3

 

106

46.9

 

MMP-11

             

   Negative

215

32

14.9

<0.0001

65

30.2

<0.0001

76

35.3

0.46

93

43.3

0.60

   Positive

322

132

41.0

 

198

61.5

 

124

38.5

 

132

41.0

 

MMP-2

             

   Negative

276

41

14.9

<0.0001

-

-

 

89

32.2

0.017

110

39.9

0.36

   Positive

263

123

46.8

 

-

-

 

111

42.2

 

115

43.7

 

uPA

             

   Negative

374

81

21.7

<0.0001

147

39.3

<0.0001

127

34.0

0.016

143

38.2

0.017

   Positive

160

81

50.6

 

115

71.9

 

72

45.4

 

79

49.4

 
  1. HSP, heat-shock protein; MMP, matrix metalloproteinase; Pos, positive; TIMP, tissue inhibitor of metalloproteases; uPA, urokinase-type plasminogen activator.